Cardiovascular and renal outcomes, and mortality in Danish patients with type 2 diabetes who initiate empagliflozin versus GLP1-RA: A Danish nationwide comparative effectiveness study (EMPLACE)

First published 04/06/2019

Last updated 02/04/2024

EU PAS number:

EUPAS29985

Study

Ongoing

Documents

Study protocol

Initial protocol

RWE Empa and Lira

English (909.98 KB - PDF)View document

Updated protocol

emplace-nis-study-protocol-version-03

First published: 22/02/2024

English (359.73 KB - PDF)View document

Study results

Study report

Other information

Publications

Study publications

Secondary tabs